Enzalutamide
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Carcinoma Metastatic to the Bone
Conditions
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
Trial Timeline
Nov 30, 2015 → May 3, 2019
NCT ID
NCT02384382About Enzalutamide
Enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Prostate Carcinoma Metastatic to the Bone. The current trial status is completed. This product is registered under clinical trial identifier NCT02384382. Target conditions include Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Carcinoma Metastatic to the Bone were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05404139 | Phase 2 | Recruiting |
| NCT02749903 | Phase 2 | Active |
| NCT02799745 | Phase 2 | Completed |
| NCT02750358 | Phase 2 | Active |
| NCT02605863 | Phase 2 | Terminated |
| NCT02384382 | Phase 2 | Completed |
| NCT02441517 | Approved | Terminated |
| NCT02507570 | Phase 2 | Completed |
| NCT02495974 | Pre-clinical | Completed |
| NCT02203695 | Phase 2 | Completed |
| NCT02288936 | Phase 2 | Completed |
| NCT02669771 | Pre-clinical | Completed |
| NCT02124668 | Phase 2 | Completed |
| NCT03297385 | Phase 2 | Completed |
| NCT02116582 | Approved | Completed |
| NCT02099864 | Phase 2 | Completed |
| NCT01977651 | Approved | Completed |
| NCT02138162 | Phase 1 | Completed |
| NCT01889238 | Phase 2 | Completed |
| NCT01663415 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Prostate Carcinoma Metastatic to the Bone